The sustained PGE release matrix improves neovascularization and skeletal muscle regeneration in a hindlimb ischemia model.

Date publication

février 2022

Journal

Journal of nanobiotechnology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BENKIRANE-JESSEL Nadia

Tous les auteurs :
Huang H, Chen S, Cheng H, Cao J, Du W, Zhang J, Chang Y, Shen X, Guo Z, Han Z, Hua G, Han ZC, Benkirane-Jessel N, Chang Y, Li Z

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35209908

Résumé

The promising therapeutic strategy for the treatment of peripheral artery disease (PAD) is to restore blood supply and promote regeneration of skeletal muscle regeneration. Increasing evidence revealed that prostaglandin E (PGE), a lipid signaling molecule, has significant therapeutic potential for tissue repair and regeneration. Though PGE has been well reported in tissue regeneration, the application of PGE is hampered by its short half-life in vivo and the lack of a viable system for sustained release of PGE.

Mots clés

Angiogenesis, Hindlimb ischemia (HI), Molecular imaging, Muscle regeneration, MyoD1, Prostaglandin E2 (PGE2), Sustained release

Référence

J Nanobiotechnology. 2022 Feb 24;20(1):95